Of course, if you don't impose these limits, the costs must be borne by the collective insured. However, if there is one government/single payer insurer, nobody would ever dream up the insane idea of saying, hey, if you're really fucked, we'll stop paying your health bills, so we can shave off a few dollars of everyone's premiums.
Lowering premiums allows insurers to win customers away from competing insurers. It's e.g. why HP sells business laptops with awful LCD panels. It's not because HP makes fat profits on each laptop (their margins are razor thin). It's because the lower price allows them to take sales away from competitors.
> However, if there is one government/single payer insurer, nobody would ever dream up the insane idea of saying, hey, if you're really fucked, we'll stop paying your health bills, so we can shave off a few dollars of everyone's premiums.
Of course they would! You think government bureaucrats aren't under pressure to control outlays? https://www.dailykos.com/stories/2017/5/8/1660050/-Death-Pan...
> In the UK, the NHS has a system based on QALYs — quality-of-life years. In crude terms, it values a year of normal health at £30,000, so if the proposed course of treatment will cost £150,000, the patient would need to have good prospects of having five years of normal life once the treatment is over to get it. For a patient who would need assistance to live because they can’t walk more than a few steps or what have you, the QALY figure might drop to £15,000, so the patient would have to have an expectancy of 10 years of assisted life to get the treatment.
Note that in the example in the story, the lifetime limit was $500,000, or 380,000 pounds. In the UK, the guy would've needed to live 12-13 years to justify spending that much. He had an aggressive cancer and died a year later, while receiving treatment. Under the U.K. system, the NHS would've been willing to pay well under $100,000 with that prognosis.
The idea that "one government/single payer insurer" systems wouldn't have these sorts of limits is the product of the exact gas-lighting I was complaining about. By focusing on the insurance companies, and the fictional fat profit margins out of which benefits can be paid for with no cost to rate payers, it totally obscures the fact that, at the end of the day, a functioning healthcare system needs to make decisions about when to cut off care.
This is simply untrue.
There's too much wrong with your link to debunk it. It's almost entirely wrong. Mostly, there is a different QALY threshold applied when drugs are used for people with life expectancy of under 24 months, and also they're using an unsourced value for QALYs.
> Lowering premiums allows insurers to win customers away from competing insurers.
Absolutely. That's what leads to competition with insurance plans that are superficially more attractive ("hey, cheaper premiums"), while basically nullifying the benefits of insurance (by making you and your family broke when things turn bad - and then you die).
The alternate system doesn't need to optimise for "optics" & sales, but can optimise eg for QALYs.
Of course neither system can overcome the fundamental issue that you can't pay for unlimited treatment for all. But quite evidently, the US system leads to harrowing quandaries for many ill people and their families, worse overall health outcomes, higher overall costs, and richer health insurance CEOs than what's done in all other developed countries; and I still don't understand why you appear to defend it.
We're specifically talking about cancer treatment in this thread, where the data is pretty clear: the US has dramatically better survival rates for cancer in the US, and the gap is even wider for forms of cancer which are considered highly treatable.
Yes, people in the US pay a lot for cancer treatment, but the overall outcomes are not worse.
No, the US massively over-tests and over-diagnoses cancer at very early stages, but this does not lead to better quality of life nor to longer life.
Prostate cancer is considered one of the most treatable forms of cancer. It's lethal if not treated. But given the proper intervention, a person can live for literally years (if not decades). The treatment isn't fun, but it's very effective, and most people consider it better than, you know, death. As of a few years ago, the survival rate for people with prostate cancer was over 90% in the US. People are actually more likely to die from an unrelated cause than they are to die from prostate cancer after treatment.
The UK, on the other hand, has an abysmal track record of treating prostate cancer - worse than every other OECD country, in fact. As of a few years ago, the survival rate was barely more than 50%. That is shameful , and it's ridiculous to dismiss that as "overdiagnosis".
https://academic.oup.com/jnci/article/94/13/981/2519795
> Background: Overdiagnosis of clinically insignificant prostate cancer is considered a major potential drawback of prostate-specific antigen (PSA) screening. Quantitative estimates of the magnitude of this problem are, however, lacking. We estimated rates of prostate cancer overdiagnosis due to PSA testing that are consistent with the observed incidence of prostate cancer in the United States from 1988 through 1998. Overdiagnosis was defined as the detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime.
> Methods: We developed a computer simulation model of PSA testing and subsequent prostate cancer diagnosis and death from prostate cancer among a hypothetical cohort of two million men who were 60–84 years old in 1988. Given values for the expected lead time—that is, the time by which the test advanced diagnosis—and the expected incidence of prostate cancer in the absence of PSA testing, the model projected the increase in population incidence of prostate cancer associated with PSA testing. By comparing the model-projected incidence with the observed incidence derived from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry data, we determined the lead times and corresponding overdiagnosis rates that were consistent with the observed data.
> Results: SEER data on prostate cancer incidence from 1988 through 1998 were consistent with overdiagnosis rates of approximately 29% for whites and 44% for blacks among men with prostate cancers detected by PSA screening.
> Conclusions: Among men with prostate cancer that would be detected only at autopsy, these rates correspond to overdiagnosis rates of, at most, 15% in whites and 37% in blacks. The observed trends in prostate cancer incidence are consistent with considerable overdiagnosis among PSA-detected cases. However, the results suggest that the majority of screen-detected cancers diagnosed between 1988 and 1998 would have presented clinically and that only a minority of cases found at autopsy would have been detected by PSA testing.
That's a lot of people being put through unpleasant surgery that has considerable side effects for no benefit.
See also this: https://scienceblog.cancerresearchuk.org/2018/03/06/overdiag...
The methodology of that study is highly suspect, but even if we took it at face value - the magnitude of the effect that they propose is nowhere near enough to explain the difference in survival rates by overdiagnosis alone. It's a drop in the bucket.
I thought the US had bad preventative healthcare.
Any sources you’d like to share? Sounds like BS.
https://scienceblog.cancerresearchuk.org/2018/03/06/overdiag...
That's a pretty significant exception, from the perspective of "designing" a social order.
It's a brute fact that humans measure their well-being in part by comparing their situations to those of their neighbors and of others with whom they come into contact. [0] People can become disgruntled, even envious, when they discover that they want things that others have but they don't. It's a fact of life: natural selection has hard-wired us to experience at least mild envy, which motivates us to try to improve our lot (by fair means or foul).
So how should we respond to that brute fact? I used to think that folks who resented high executive compensation should just get over it, or go and earn such compensation themselves. I remember listening approvingly to the old Eddie Chiles TV commercials: Don't have an oil well? Get one! [1]
These days, on the other hand, I'm increasingly realizing that this is unrealistic, and also that we broadcast an unrealistic message: You, too, can make it to the executive suite and pull down the big bucks if you just work hard enough and smart enough, starting when you're young. But that's akin to saying that if you just work hard enough and smart enough, you can play for an NBA team or win the British Open golf tournament. That's certainly true for a few people; for the vast majority, though, that message seems delusional and perhaps even fraudulent.
That in turn has led me to think that high executive comp, and the sense of vague disgruntlement among others to which it contributes, might be akin to the unremarkable public water pump that was discovered to have been the source of London's deadly 1854 Broad Street cholera outbreak, in which more than 600 people died in just a couple of weeks: [2] To outward appearances the water pump was innocuous and beneficial, but in reality it was silently poisoning the community and attacking the social fabric.
[0] https://academic.oup.com/qje/article-abstract/120/3/963/1841...
[1] https://en.wikipedia.org/wiki/Eddie_Chiles
[2] https://en.wikipedia.org/wiki/1854_Broad_Street_cholera_outb...
The decision of whether to have limits on how much you're willing to spend for one case exists whether you have a private system or a public system. Either way, the public is on the hook if the system is more generous.